VERACYTE, INC.VCYT

時価総額

PER

	2014年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日
Testing revenue	-	107	102	188	251	327
Product revenue	-	1	10	11	13	16
Biopharmaceutical and other revenue	-	-	-	20	33	19
Total revenue	38	120	117	220	297	361
Testing revenue	-	-	36	59	75	89
Product revenue	-	-	5	6	8	9
Biopharmaceutical and other revenue	-	-	-	10	18	15
Cost of revenue	17	36	-	-	-	-
Research and development	10	15	17	30	41	57
Selling and marketing	22	54	52	80	98	101
General and administrative	19	29	37	101	77	86
Intangible asset amortization	-	1	5	16	21	21
Impairment of long-lived assets	-	-	-	-	-	68
Total operating expenses	-	135	153	301	338	447
Intangible asset amortization	-	1	5	16	21	21
Total operating expenses	-	135	153	301	338	447
Loss from operations	-29	-15	-35	-82	-41	-86
Other income, net	0	3	1	0	5	9
Loss before income tax benefit	-	-	-	-82	-36	-77
Income Tax Expense (Benefit)	-	-	-	-6	0	-2
Net loss	-	-	-35	-76	-37	-74
Earnings Per Share, Basic	-	-	-	-1.11	-0.51	-1.02
Earnings Per Share, Diluted	-	-	-	-1.11	-0.51	-1.02